Does oral salbutamol improve fatigue in multiple sclerosis? A pilot placebo-controlled study.

BACKGROUND: Because MS-related fatigue could be associated with enhanced proinflammatory cytokine production, drugs with immunomodulatories properties, such as salbutamol, may represent an alternative treatment. We aimed to evaluate the effect of salbutamol on MS-related fatigue. METHODS: Thirty patients with relapsing-remitting MS who were between 18 and 69 years old, and suffering from fatigue, were evaluated with the Fatigue Severity Scale (FSS) and the Brazilian version of the neurological fatigue index for multiple sclerosis (NFI/MS-BR). They received salbutamol 2 mg twice a day or a placebo in a pilot randomized, double-masked placebo-controlled trial. The primary outcome was the change in the FSS score at the end of 90 days. The secondary outcome was the efficacy, represented by changes in their scores on the NFI/MS-BR subdomains (in the same period) and the Expanded Disability Status Scale (EDSS) at the end of 90 days. RESULTS: Thirty subjects were allocated to receive either salbutamol (14) or a placebo (16). There was no superiority of salbutamol over the placebo in the FSS outcome at 30 (p ==0.498), 60 (p = 0.854) and 90 (p = 0.240) days. There was no a significant decrease in the proportion of patients with severe or moderate fatigue in the salbutamol group at the end of the follow-up. The scores on the NFI/MS-BR and its subscales did not improve significantly with treatment. No significant difference was observed in the EDSS outcome (p = 0.313). No serious adverse events were found. An increase in heart rate was evident in the salbutamol group only in the first 30 days, but without statistical significance in relation to placebo (p = 0.077). CONCLUSION: Treatment with salbutamol does not improve fatigue in patients with relapsing-remitting MS.

Analysis of 621 death certificates issued from 1998 to 2007 in Curitiba, Brazil, mentioning epilepsy, epileptic seizures and/or status epilepticus.

PURPOSE: This study aims to study death records mentioning epilepsy, epileptic seizures and/or status epilepticus, in order to survey the population demographics and associated medical conditions, making it possible to outline the patient's profile. METHODS: A qualitative analysis was performed on the data gathered from death certificates from the Curitiba county records ranging from 1998 to 2007 bracket, in which epilepsy, seizure and/or status epilepticus were mentioned as the basic, intermediate, immediate or associated cause of death. RESULTS: Epilepsy was mentioned on 621 death cases in this 10-year-period. The deaths were mainly of male individuals (57.3%), Caucasian (71.6%), single (48.6%) and aged between 20 and 60 years (51.8%). Most of those who died were hospitalized patients (62.5%) and in 64.3% of the reported deaths, the patient received medical care during the event that led to his/her death. Epilepsy itself was considered to be the cause of death in 44%, followed by status epilepticus (9.7%). The most common intermediary and immediate causes were pulmonary infections (11.1%) and cardiac arrest (19.2%), respectively DISCUSSION: Hospitalized younger Caucasian males with epilepsy were the most common cases in this 10-year-period survey. Pulmonary infections were a common finding, but other aspects such as previous trauma, cerebrovascular disease or neoplasm were eventual associated factors. Public health and medical preventative measures can be planned based on the results of this study.